Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients

Periodontitis Clinical Trial

Official title:

A Phase 2, Randomized, Double-blind, Parallel, Placebo-controlled Study to Evaluate Efficacy and Safety of Local Injection of Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05924373
• Other study ID #: SH-hDP-MSC-102
• Status: Recruiting
• Phase: Phase 2
• Start date: November 27, 2023
• Est. completion date: September 30, 2026

Study information

• Verified date: May 2023
• Source: Peking University Third Hospital
• Contact: Xiao Wang, Master
• Phone: +86 010-82266334
• Email: bysykqpeking[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective:To evaluate the efficacy of different administration protocols of human dental pulp mesenchymal stem cells for the treatment of chronic periodontitis patients. The secondary objective:To evaluate the safety of different administration protocols of human dental pulp mesenchymal stem cells for the treatment of chronic periodontitis patients. The exploratory objective:To investigate the effects of human dental pulp mesenchymal stem cells on biomarkers in gingival crevicular fluid in chronic periodontitis patients.

Description:

This is a multicenter, randomized, double-blind, parallel, placebo-controlled study, including three treatment groups which are single-dose group, two-dose group (low-dose), and two-dose group (high-dose). The patients of single-dose group will receive only one dose on day 1 (D1), and the patients of two-dose groups will receive one dose on D1 and D90 respectively. 68 participants will be enrolled in each group, and be randomized (3:1) to receive human dental pulp mesenchymal stem cells (hDP-MSCs) or placebo (normal saline). Participants in the single-dose group and the two-dose group (high-dose) will receive local injection of 1.0 × 107 hDP-MSCs (0.6mL normal saline suspension) / periodontal defect site or 0.6mL normal saline / periodontal defect site, and participants in the two-dose group (low-dose) will receive local injection of 1.0 × 106 hDP-MSCs (0.6mL normal saline suspension) / periodontal defect site or 0.6mL normal saline / periodontal defect site. All participants will receive basic periodontal treatment simultaneously. Dosing interval: the dosing interval is set at 89 days, which is based on the results of preclinical trials of hDP-MSCs, the improvement of periodontitis observed on D90 after hDP-MSCs administration, and good safety profile in phase 1 clinical trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 204
• Est. completion date: September 30, 2026
• Est. primary completion date: March 7, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participants are eligible to be included in the study only if all of the following criteria apply: 1)18 to 65 years old (including threshold), unlimited gender; 2)Radiological examination of the periodontal defect site shows angular bone defect; 3)The probing depth (PD) at the periodontal defect site is 4 to 8 mm at baseline; 4)Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures; 5)Voluntarily participate in the clinical study, understand and sign the informed consent;

Exclusion Criteria:

• Participants are excluded from the study if any of the following criteria apply:

1. Participants with severe periodontal diseases (alveolar bone resorption exceeds two-thirds of the tooth root length) which affect the investigator's judgment;

2. The grade of studied tooth looseness = grade 3 at baseline (only buccolingual movement is defined as grade 1; buccolingual and mesiodistal movement is grade 2; vertical loosening is grade 3);

3. The studied tooth with occlusal trauma which affect the investigator's judgment;

4. Participants with surgical treatment of previous periodontal defect sites and adjacent periodontal tissues;

5. Participants with non-steroid anti-inflammatory drug, steroid hormone therapy, and/or other hormone (except topical hormones) treatment within past 3 months of the screening visit, and/or previous use of bisphosphonates;

6. Participants with severe systemic infection within past 3 months of the screening visit, or antibiotics treatment within past 72h of the screening visit;

7. Participants with uncontrolled hypertension within 1 month before screening (defined as sitting systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg after receiving the optimal antihypertensive therapy);

8. Participants with severe or uncontrolled diseases in any system (cardiac, hepatic, renal, respiratory, hematologic, endocrine, nervous, or psychiatric);

9. Participants are known to be allergic to any materials that may be used during surgery (allergy-prone constitution or history of allergy to blood products);

10. Any of the following abnormalities in clinical laboratory tests at screening: ALT > 3 ULN, total bilirubin > 1.5 ULN, serum creatinine > 1.5 ULN, international normalized ratio (INR) = 1.5 ULN or activated partial thromboplastin time (APTT) = 1.5 ULN (except for patients receiving anticoagulation therapy), Hb < 80 g/L, or PLT < 75.0×109/L;

11. Positive result for any of the following tests at screening: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody (TP-Ab);

12. Females who are pregnant or breastfeeding;

13. Participants and their partners who plan to conceive or do not agree to use the effective non-pharmacological method of contraceptive during the trial from screening visit to 6 months after the end of the trial;

14. Participants participated in other clinical studies within past 3 months of the screening visit;

15. Participants with a history of smoking addiction within past 12 months of the screening visit (the number of cigarettes smoked per day = 10); Other circumstances deemed inappropriate by the investigator.

Related Conditions & MeSH terms

• Chronic Periodontitis
• Periodontitis

Intervention

Drug:
• Human Dental Fulp Stem Cells
Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijng

Sponsors (2)

Lead Sponsor	Collaborator
Peking University Third Hospital	Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change from baseline in interleukin-6 (IL-6)	Changes in IL-6 baseline will be confirmed through gingival crevicular fluid detection at D90 D180 D360 and D720	at baseline, 90 days, 180 days,360 days,720 days
Other	Change from baseline in tumor necrosis factor-alpha (TNF-a)	Changes in TNF-a baseline will be confirmed through gingival crevicular fluid detection at D90 D180 D360 and D720	at baseline, 90 days, 180 days,360 days,720 days
Other	Change from baseline in matrix metalloproteinase-8 (MMP-8)	Changes in MMP-8 baseline will be confirmed through gingival crevicular fluid detection at D90 D180 D360 and D720	at baseline, 90 days, 180 days,360 days,720 days
Other	Change from baseline in interleukin-1beta (IL-1ß)	Changes in IL-1ß baseline will be confirmed through gingival crevicular fluid detection at D90 D180 D360 and D720	at baseline, 90 days, 180 days,360 days,720 days
Other	Change from baseline in osteoprotegerin (OPG)	Changes in OPG baseline will be confirmed through gingival crevicular fluid detection at D90 D180 D360 and D720	at baseline, 90 days, 180 days,360 days,720 days
Other	Changes from baseline in height of the periodontal bone defect	Changes from baseline in height of the periodontal bone defect which will be examined by CBCT at D360 and D720	at baseline, 360 days,720 days
Other	Change from baseline in Clinical Attachment Level (AL)	Clinical Attachment Level (AL) may be assessed to the nearest millimeter by means of a graduated probe and expressed as the distance in millimeters from the CEJ to the bottom of the probeable gingival/periodontal pocket	at baseline, 360 days,720 days
Other	Change from baseline in Probing Depth (PD)	The probing depth is the distance from the gingival margin to the bottom of the gingival sulcus/pocket, is measured to the nearest millimeter by means of periodontal probe	at baseline, 360 days,720 days
Other	Change from baseline in Tooth Mobility (TM)	The continuous loss of the supporting tissues during periodontal disease progression may result in increased tooth mobility, which is divided into 3 degree: I°, II°, and III°. Changes from baseline in tooth mobility will be recorded	at baseline, 360 days,720 days
Other	Change from baseline in Gingival recession (GR)	Exposure of the tooth through apical migration of the gingiva is called gingival recession. Recorded as the distance in millimeters from the CEJ to the gingival margin	at baseline, 360 days,720 days
Other	Change from baseline in Probing bleeding on probing (BOP)	A periodontal probe is inserted to the "bottom" of the gingival/periodontal pocket applying light force and is moved gently along the tooth (root) surface. If bleeding is provoked by this examination, the site examined is considered bleeding on probing-positive and, hence, inflamed. Probing Bleeding Index is divided into 5 grades: 0, 1, 2, 3 and 4.	at baseline, 360 days,720 days
Primary	Changes from baseline in height of the periodontal bone defect	Changes from baseline in height of the periodontal bone defect which will be examined by CBCT at D90±7 and D180±14 (primary efficacy endpoint)	at baseline, 90 days, 180 days
Secondary	Changes from baseline in respiration rate of Vital Signs	Respiratory rate, in beats per minute	within 180 days after administration
Secondary	Changes from baseline in heart rate of Vital Signs	Heart rate in beats per minute	within 180 days after administration
Secondary	Changes from baseline in blood pressure of Vital Signs	Blood pressure in mmHg, both systolic and diastolic blood pressure will be measured.	within 180 days after administration
Secondary	Changes from baseline in body temperature of Vital Signs	Body temperature in Celsius degree	within 180 days after administration
Secondary	Changes from baseline in red blood cell count of Laboratory Examination	Red blood cell count in whole blood is reported in the form of number	within 180 days after administration
Secondary	Changes from baseline in white blood cell count of Laboratory Examination	White blood cell count in whole blood is reported in the form of number	within 180 days after administration
Secondary	Changes from baseline in neutrophil count of Laboratory Examination	Neutrophil count in whole blood is reported in the form of number	within 180 days after administration
Secondary	Changes from baseline in lymphocyte count of Laboratory Examination	Lymphocyte count in whole blood is reported in the form of number	within 180 days after administration
Secondary	Changes from baseline in platelet count of Laboratory Examination	Platelet count in whole blood is reported in the form of number	within 180 days after administration
Secondary	Changes from baseline in hemoglobin of Laboratory Examination	Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.	within 180 days after administration
Secondary	Changes from baseline in PT of Laboratory Examination	Prothrombin time (PT) is a screening test for exogenous coagulation factors	within 180 days after administration
Secondary	Changes from baseline in INR of Laboratory Examination	International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.	within 180 days after administration
Secondary	Changes from baseline in APTT of Laboratory Examination	Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors	within 180 days after administration
Secondary	Changes from baseline in total bilirubin of Laboratory Examination	Changes of total bilirubin concentration (µmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in direct bilirubin of Laboratory Examination	Changes of direct bilirubin concentration (µmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in ALT of Laboratory Examination	Changes of ALT concentration (U/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in AST of Laboratory Examination	Changes of AST concentration (U/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in total protein of Laboratory Examination	Changes of total protein concentration (g/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in albumin of Laboratory Examination	Changes of albumin concentration (g/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in total bile acid of Laboratory Examination	Changes of total bile acid concentration (µmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in urea of Laboratory Examination	Changes of urea concentration (mmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in creatinine of Laboratory Examination	Changes of creatinine concentration (µmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in uric acid of Laboratory Examination	Changes of uric acid concentration (µmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in glucose of Laboratory Examination	Changes of glucose concentration (mmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in potassium of Laboratory Examination	Changes of potassium concentration (mmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in sodium of Laboratory Examination	Changes of sodium concentration (mmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in chlorine of Laboratory Examination	Changes of chlorine concentration (mmol/L) in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in Detection of infectious diseases of Laboratory Examination	It refers to infectious diseases screening	within 180 days after administration
Secondary	Changes from baseline in IgA of Laboratory Examination	Changes of IgA concentration (g/L)in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in IgG of Laboratory Examination	Changes of IgG concentration (g/L)in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in IgM of Laboratory Examination	Changes of IgM concentration (g/L)in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in total IgE of Laboratory Examination	Changes of total IgE concentration (g/L)in serum will be recorded	within 180 days after administration
Secondary	Changes from baseline in Pregnancy test of Laboratory Examination	Pregnancy test will be tested in female subjects	within 180 days after administration
Secondary	Changes from baseline in urine specific gravity of Laboratory Examination	Changes of urine specific gravity will be recorded	within 180 days after administration
Secondary	Changes from baseline in urine pH of Laboratory Examination	Changes of urine pH value will be recorded	within 180 days after administration
Secondary	Changes from baseline in urine glucose of Laboratory Examination	Changes of urine glucose will be examined by qualitative test (positive or negative)	within 180 days after administration
Secondary	Changes from baseline in urine protein of Laboratory Examination	Changes of urine protein will be examined by qualitative test (positive or negative)	within 180 days after administration
Secondary	Changes from baseline in urine ketone body of Laboratory Examination	Changes of urine ketone body will be examined by qualitative test (positive or negative)	within 180 days after administration
Secondary	Changes from baseline in urine white blood cell of Laboratory Examination	Changes of white blood cell in urine will be examined by qualitative test (positive or negative)	within 180 days after administration
Secondary	Changes from baseline in urine bilirubin of Laboratory Examination	Changes of urine bilirubin will be examined by qualitative test (positive or negative)	within 180 days after administration
Secondary	Changes from baseline in urine occult blood of Laboratory Examination	Changes of urine occult blood will be examined by qualitative test (positive or negative)	within 180 days after administration
Secondary	Changes from baseline in ECG PR interval	The cardiac rhythm is showed in 12 Leads Ambulatory Electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded.	within 180 days after administration
Secondary	Changes from baseline in ECG QRS interval	The cardiac rhythm is showed in 12 Leads Ambulatory Electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded.	within 180 days after administration
Secondary	Changes from baseline in ECG RR interval	The cardiac rhythm is showed in 12 Leads Ambulatory Electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded.	within 180 days after administration
Secondary	Changes from baseline in ECG QT interval	The cardiac rhythm is showed in 12 Leads Ambulatory Electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded.	within 180 days after administration
Secondary	Incidence of Treatment-Emergent Adverse Event	Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events during the study period, and the severity of adverse events is determined according to the NCI CTCAE version 5.0	within 180 days after administration
Secondary	Change from baseline in Clinical Attachment Level (AL)	Clinical Attachment Level (AL) may be assessed to the nearest millimeter by means of a graduated probe and expressed as the distance in millimeters from the CEJ to the bottom of the probeable gingival/periodontal pocket	at baseline, 90 days, 180 days
Secondary	Change from baseline in Tooth Mobility (TM)	The continuous loss of the supporting tissues during periodontal disease progression may result in increased tooth mobility, which is divided into 3 degree: I°, II°, and III°. Changes from baseline in tooth mobility will be recorded	at baseline, 90 days, 180 days
Secondary	Change from baseline in Probing Depth (PD)	The probing depth is the distance from the gingival margin to the bottom of the gingival sulcus/pocket, is measured to the nearest millimeter by means of periodontal probe	at baseline, 90 days, 180 days
Secondary	Change from baseline in Gingival recession (GR)	Exposure of the tooth through apical migration of the gingiva is called gingival recession. Recorded as the distance in millimeters from the CEJ to the gingival margin	at baseline, 90 days, 180 days
Secondary	Change from baseline in Probing bleeding on probing (BOP)	A periodontal probe is inserted to the "bottom" of the gingival/periodontal pocket applying light force and is moved gently along the tooth (root) surface. If bleeding is provoked by this examination, the site examined is considered bleeding on probing-positive and, hence, inflamed. Probing Bleeding Index is divided into 5 grades: 0, 1, 2, 3 and 4.	at baseline, 90 days, 180 days